Literature DB >> 23407451

The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation.

Julia Durzyńska1, Anastassios Philippou, Becky K Brisson, Michelle Nguyen-McCarty, Elisabeth R Barton.   

Abstract

IGF-I is a key regulator of muscle development and growth. The pre-pro-peptide produced by the Igf1gene undergoes several posttranslational processing steps to result in a secreted mature protein, which is thought to be the obligate ligand for the IGF-I receptor (IGF-IR). The goals of this study were to determine what forms of IGF-I exist in skeletal muscle, and whether the mature IGF-I protein was the only form able to activate the IGF-IR. We measured the proportion of IGF-I species in murine skeletal muscle and found that the predominant forms were nonglycosylated pro-IGF-I and glycosylated pro-IGF-I, which retained the C-terminal E peptide extension, instead of mature IGF-I. These forms were validated using samples subjected to viral expression of IGF-I combined with furin and glycosidase digestion. To determine whether the larger molecular weight IGF-I forms were also ligands for the IGF-IR, we generated each specific form through transient transfection of 3T3 cells and used the enriched media to perform kinase receptor activation assays. Compared with mature IGF-I, nonglycosylated pro-IGF-I had similar ability to activate the IGF-IR, whereas glycosylation of pro-IGF-I significantly reduced receptor activation. Thus, it is important to understand not only the quantity, but also the proportion of IGF-I forms produced, to evaluate the true biological activity of this growth factor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407451      PMCID: PMC3578996          DOI: 10.1210/en.2012-1992

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

1.  Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro.

Authors:  M A Bach; C T Roberts; E P Smith; D LeRoith
Journal:  Mol Endocrinol       Date:  1990-06

2.  Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases.

Authors:  S J Duguay; W M Milewski; B D Young; K Nakayama; D F Steiner
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

3.  Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis.

Authors:  Briony E Forbes; Perry J Hartfield; Kerrie A McNeil; Kathy H Surinya; Steven J Milner; Leah J Cosgrove; John C Wallace
Journal:  Eur J Biochem       Date:  2002-02

4.  Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats.

Authors:  G R Adams; S A McCue
Journal:  J Appl Physiol (1985)       Date:  1998-05

5.  Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions.

Authors:  F F Vajdos; M Ultsch; M L Schaffer; K D Deshayes; J Liu; N J Skelton; A M de Vos
Journal:  Biochemistry       Date:  2001-09-18       Impact factor: 3.162

6.  Cultured human fibroblasts secrete insulin-like growth factor IA prohormone.

Authors:  C A Conover; B K Baker; R L Hintz
Journal:  J Clin Endocrinol Metab       Date:  1989-07       Impact factor: 5.958

7.  Purification from transformed mouse fibroblast of a cell growth inhibitor which is an IGF-binding protein.

Authors:  C Blat; J Villaudy; J Delbé; F Troalen; A Golde; L Harel
Journal:  Growth Factors       Date:  1992       Impact factor: 2.511

8.  Human hepatoma cells synthesize and secrete insulin-like growth factor Ia prohormone under growth hormone control.

Authors:  C A Conover; B K Baker; L K Bale; J T Clarkson; F Liu; R L Hintz
Journal:  Regul Pept       Date:  1993-10-20

Review 9.  Structural biology of insulin and IGF1 receptors: implications for drug design.

Authors:  Pierre De Meyts; Jonathan Whittaker
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

10.  Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice.

Authors:  M E Coleman; F DeMayo; K C Yin; H M Lee; R Geske; C Montgomery; R J Schwartz
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

View more
  26 in total

1.  Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy.

Authors:  Chao Li; Kent Vu; Krystina Hazelgrove; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-01       Impact factor: 4.052

2.  Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength.

Authors:  Becky K Brisson; Janelle Spinazzola; SooHyun Park; Elisabeth R Barton
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-02-25       Impact factor: 4.310

3.  Characterization of Optimal Strain, Frequency and Duration of Mechanical Loading on Skeletal Myotubes' Biological Responses.

Authors:  Athanasios Moustogiannis; Anastassios Philippou; Evangelos Zevolis; Orjona Taso; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 4.  The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity.

Authors:  Anastassios Philippou; Maria Maridaki; Spiros Pneumaticos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-05-07       Impact factor: 6.354

5.  Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction.

Authors:  James R Peña; James R Pinney; Perla Ayala; Tejal A Desai; Paul H Goldspink
Journal:  Biomaterials       Date:  2015-01-16       Impact factor: 12.479

Review 6.  Optimizing IGF-I for skeletal muscle therapeutics.

Authors:  Anastassios Philippou; Elisabeth R Barton
Journal:  Growth Horm IGF Res       Date:  2014-06-19       Impact factor: 2.372

7.  Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor.

Authors:  Mauro De Santi; Giosuè Annibalini; Elena Barbieri; Anna Villarini; Luciana Vallorani; Serena Contarelli; Franco Berrino; Vilberto Stocchi; Giorgio Brandi
Journal:  Cell Oncol (Dordr)       Date:  2015-12-23       Impact factor: 6.730

Review 8.  Role of IGF-I signaling in muscle bone interactions.

Authors:  Daniel D Bikle; Candice Tahimic; Wenhan Chang; Yongmei Wang; Anastassios Philippou; Elisabeth R Barton
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

Review 9.  Platelet-rich plasma for managing pain and inflammation in osteoarthritis.

Authors:  Isabel Andia; Nicola Maffulli
Journal:  Nat Rev Rheumatol       Date:  2013-10-01       Impact factor: 20.543

10.  Mature IGF-I excels in promoting functional muscle recovery from disuse atrophy compared with pro-IGF-IA.

Authors:  Soohyun Park; Becky K Brisson; Min Liu; Janelle M Spinazzola; Elisabeth R Barton
Journal:  J Appl Physiol (1985)       Date:  2013-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.